www.mysmartrend.com/news-briefs/...mance-healthcare-sector-inf
|
von den Studiendaten hatten sich die Marktteilnehmer wohl mehr erhofft
investors.infi.com/news-releases/...anslational-data-expansion
Ausblick für 2019
2019 Financial Guidance
Infinity ended 2018 with approximately $58.6 million in cash and investments (unaudited) and plans to report its fourth quarter and full-year 2018 financial results in March. The company is providing the following financial guidance today:
Infinity's 2019 financial guidance is based on its current operating plans, excludes additional financing or business development activities, and includes a $2 million milestone payment from PellePharm, a private company, upon initiation of a Phase 3 study for the hedgehog inhibitor program, which Infinity licensed to PellePharm in 2013.
IPI-549 is an investigational compound, and its safety and efficacy have not been evaluated by the U.S. Food and Drug Administration or any other health authority.
investors.infi.com/news-releases/...s-2019-goals-and-financial
Infinity meldet Zahlen für 2018
www.sec.gov/Archives/edgar/data/1113148/...i-1231201810xk.htm
Infinity Pharmaceuticals meldet Zahlen für Q1/19
Cash Runway
"Based on its current operational plans, Infinity expects that its existing cash, cash equivalents and available-for-sale securities will be adequate to satisfy the company's capital needs into 2H 2020."
investors.infi.com/news-releases/...company-update-and-first-0
Zahlen für Q3/19
investors.infi.com/news-releases/...company-update-and-third-0
Zahlen für 2019
"Based on its current operational plans, Infinity expects that its existing cash, cash equivalents and available-for-sale securities, including the $20.0 million received from BVF in January 2020, will be adequate to satisfy the company's capital needs into 2H 2021"
investors.infi.com/news-releases/...s-full-year-2019-financial
Zahlen für Q3/20
"Based on its current operational plans, Infinity expects that its existing cash, cash equivalents and available-for-sale securities, will be adequate to satisfy the Company's capital needs through 2021."
investors.infi.com/news-releases/...ompany-update-and-third-1
SABSC20 Präsentation
seekingalpha.com/article/...breast-cancer-symposium-slideshow
JPM Präsentation Januar 2021
seekingalpha.com/article/...lthcare-conference-2021-slideshow
Daten der Phase 2 MARIO-275 Studie von Eganelisib und Nivolumab
investors.infi.com/news-releases/...s-data-randomized-placebo
80 Mio. $ Offering
investors.infi.com/news-releases/...on-public-offering-common
Zahlen für Q1/21
–Updated TNBC data from MARIO-3 to be reported mid-year and 4Q’21–
–Update for eganelisib in PD-L1 low, 2L advanced UC patients expected mid-year–
–$92M public offering strengthens balance sheet for continued development of eganelisib–
investors.infi.com/news-releases/...st-quarter-2021-financial
Update : Phase 2 MARIO-275 Studie (UC) und Phase 2 MARIO-3 Studie (TNBC)
investors.infi.com/node/17446
Zahlen für Q3/21
" Updated safety and efficacy data will be presented at the San Antonio Breast Cancer Symposium (SABCS) Annual Meeting, December 7-10, 2021."
– Updated mTNBC data to be presented at San Antonio Breast Cancer Symposium
investors.infi.com/news-releases/...rd-quarter-2021-financial
Eganelisib Strategie-Update & Ausblick für 2022
"Infinity ended 2021 with approximately $81 million in cash and investments (unaudited) and plans to report its fourth quarter and full-year 2021 financial results in March 2022. The Company expects to end 2022 with between $25 million to $35 million in cash and investments based on its current operating plans, which excludes additional financing or business activities. The company expects net loss for 2022 to range between $45 million to $55 million."
investors.infi.com/news-releases/...lines-eganelisib-clinical
Zahlen für 2021
- Infinity expects to have cash for at least 12 months
investors.infi.com/node/17896
Zahlen für Q1/22
investors.infi.com/news-releases/...st-quarter-2022-financial
Zahlen für Q3/22
- Cash runway into 2024
- Business development discussions advancing with goal of announcing a partnership in Q1 2023
investors.infi.com/news-releases/...rd-quarter-2022-financial
Merger mit MEI-Pharma
investors.infi.com/node/18166
Das ist nicht der große Wurf, den sich die Investoren haben dürften.
Zahlen für FY22
"Wenn die Fusion abgeschlossen ist, wird das kombinierte Unternehmen voraussichtlich beim Abschluss einen Cash-Saldo von ~ 100 Millionen Dollar haben, der voraussichtlich bis Mitte 2025 den Betrieb finanzieren wird."
investors.infi.com/node/18226
www.fiercebiotech.com/biotech/...-if-mei-merger-falls-through
investors.infi.com/events-and-presentations/upcoming-events
Wem fällt etwas auf?
seekingalpha.com/news/...-vote-on-infinity-deal-until-july-23
www.meipharma.com/press-releases/...cial-meeting-stockholders
Damit könnte INFI vor dem "Bankrott" stehen, wenn nicht noch ein Wunder geschieht und irgendwo ein weißer Ritter auftaucht.
investors.infi.com/node/18411
www.fiercebiotech.com/biotech/...ed-shareholders-sinking-deal
wird vom Handel ausgesetzt
"Es kann keine Garantie dafür geben, dass es nach der erwarteten Aussetzung einen öffentlichen Markt für den Handel mit den Stammaktien des Unternehmens geben wird.“
seekingalpha.com/news/...ing-determination-letter-from-nasdaq
Chapter 11
seekingalpha.com/news/...cals-reportedly-files-for-chapter-11
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
4 | 95 | Infinity Pharma explodiert ! | Balu4u | Vassago | 02.10.23 13:04 | |
1 | Infinity Pharmaceuticals -WKN: A0LA4Y- | Tiger | Tiger | 08.08.23 17:24 | ||
3 | über Infinity | Mr. Pisoc | bebe2 | 28.07.21 20:36 |